A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer

European Journal of Cancer

Volumn 51, Issue 12, 2015, Pages 1555-1569

  Chu, Franklin M ^a   Sartor, Oliver ^b   Gomella, Leonard ^c   Rudo, Todd ^d   Somerville, Matthew C ^d,e   Hereghty, Belinda ^d,e   Manyak, Michael J ^d  

^a San Bernardino Urological Associates   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

^e PAREXEL INTERNATIONAL   (United States)

Author keywords

Androgen deprivation therapy (ADT); Bicalutamide; Castration resistant prostate cancer (CRPC); Dutasteride; Prostate specific antigen (PSA)

Indexed keywords

BICALUTAMIDE; DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AZASTEROID; GONADORELIN; NITRILE; STEROID 5ALPHA REDUCTASE INHIBITOR; TOLUENESULFONIC ACID DERIVATIVE;

ACUTE RESPIRATORY FAILURE; ADD ON THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; ATELECTASIS; ATRIAL FIBRILLATION; BACKACHE; BODY MASS; CANCER GROWTH; CARDIOPULMONARY INSUFFICIENCY; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC KIDNEY FAILURE; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIGITAL RECTAL EXAMINATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EJACULATION DISORDER; FAILURE TO THRIVE; FATIGUE; GLEASON SCORE; GYNECOMASTIA; HEADACHE; HEART INFARCTION; HIP FRACTURE; HOT FLUSH; HUMAN; HUMERUS FRACTURE; HYPOXIA; IMPOTENCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIBIDO DISORDER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SUICIDE; TIME TO TREATMENT; TREATMENT RESPONSE; URINARY TRACT INFECTION; CLINICAL TRIAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZASTEROIDS; DOUBLE-BLIND METHOD; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITRILES; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TOSYL COMPOUNDS;

EID: 84936846213     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.04.028     Document Type: Article

References (35)

1. M. Roach 3rd. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer Cancer 120 2014 1620 1629
2. D.A. Loblaw, K.S. Virgo, and R. Nam Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 2007 1596 1605
3. T. Karantanos, P.G. Corn, and T.C. Thompson Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches Oncogene 32 2013 5501 5511
4. M.R. Smith, F. Kabbinavar, and F. Saad Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 23 2005 2918 2925
5. M.R. Smith, R. Cook, K.A. Lee, and J.B. Nelson Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer Cancer 117 2011 2077 2085
6. A.A. Azad, E.K. Beardsley, and S.J. Hotte A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naive castration-resistant prostate cancer Invest New Drugs 32 2014 746 752
7. R.B. Montgomery, E.A. Mostaghel, and R. Vessella Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
8. R.J. Auchus The backdoor pathway to dihydrotestosterone Trends Endocrinol Metab 15 2004 432 438
9. E.A. Mostaghel, B. Montgomery, and P.S. Nelson Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease Urol Oncol 27 2009 251 257
10. M. Stanbrough, G.J. Bubley, and K. Ross Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
11. Avodart (dutasteride) - Summary of Product Characteristics. Available at: < https://www.medicines.org.uk/emc/medicines/11618 > [last update 10 October 2013]. Accessed November 2014.
12. H.N. Bramson, D. Hermann, K.W. Batchelor, F.W. Lee, M.K. James, and S.V. Frye Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR J Pharmacol Exp Ther 282 1997 1496 1502
13. F. Azzouni, A. Godoy, Y. Li, and J. Mohler The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases Adv Urol 2012 2012 530121
14. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
15. N.E. Fleshner, M.S. Lucia, and B. Egerdie Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial Lancet 379 2012 1103 1111
16. M. Gleave, J. Qian, and C. Andreou The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study Prostate 66 2006 1674 1685
17. M. Ayub, and M.J. Levell The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins J Steroid Biochem 33 1989 251 255
18. O. Sartor, L.G. Gomella, P. Gagnier, K. Melich, and R. Dann Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design Can J Urol 16 2009 4806 4812
19. Y. Fujii, S. Kawakami, and H. Masuda Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy BJU Int 97 2006 1184 1189
20. M.E. Stokes, C.S. Davis, and C.G. Koch Categorical data analysis using the SAS system 2nd ed. 2000 SAS Institute, Inc. Cary, North Carolina p. 46-57
21. M. Lodde, L. Lacombe, and Y. Fradet Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer Urology 76 2010 1189 1193
22. M.R. Smith, F. Saad, and S. Oudard Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time J Clin Oncol 31 2013 3800 3806
23. J.W. Denham, D. Joseph, and D.S. Lamb Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial Lancet Oncol 15 2014 1076 1089
24. J.B. Nelson, W. Love, and J.L. Chin Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer Cancer 113 2008 2478 2487
25. K. Miller, J.W. Moul, and M. Gleave Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer Prostate Cancer Prostatic Dis 16 2013 187 192
26. M. Nakabayashi, L. Werner, and K.D. Courtney Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer BJU Int 110 2012 1729 1735
27. E.K. Beardsley, S.J. Hotte, and S. North A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer Invest New Drugs 30 2012 1652 1659
28. I. Wu, and C.S. Modlin Disparities in prostate cancer in African American men: what primary care physicians can do Cleve Clin J Med 79 2012 313 320
29. I.J. Powell, C.H. Bock, J.J. Ruterbusch, and W. Sakr Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity J Urol 183 2010 1792 1796
30. C.J. Ryan, A. Molina, and J. Li Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial J Clin Oncol 31 2013 2791 2798
31. R.M. Merrill, and J.S. Bird Effect of young age on prostate cancer survival: a population-based assessment (United States) Cancer Causes Control 13 2002 435 443
32. D.W. Lin, M. Porter, and B. Montgomery Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study Cancer 115 2009 2863 2871
33. Y.K. Loke, R. Ho, and M. Smith Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride J Clin Pharm Ther 38 2013 405 415
34. Casodex (bicalutamide). Summary of Product Characteristics. Available at: < https://www.medicines.org.uk/emc/medicine/2273 > [last update 4 August 2013]. Accessed November 2014.
35. M.A. Titus, M.J. Schell, F.B. Lih, K.B. Tomer, and J.L. Mohler Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin Cancer Res 11 2005 4653 4657